Literature DB >> 10493605

Antiviral activity of enterocin CRL35 against herpesviruses.

M B Wachsman1, M E Farías, E Takeda, F Sesma, A P de Ruiz Holgado, R A de Torres, C E Coto.   

Abstract

Enterocin CRL35 is an antibacterial polypeptide of 3.5 x 10(3) Da produced by Enterococcus faecium CRL35. A series of experiments are described that show the enterocin also had antiviral activity against thymidine-kinase positive (tk+) and deficient (tk-) strains of herpes simplex (HSV) type 1 and 2 in Vero and BHK-21 cells. This activity was observed at 100 microg/ml, 15-fold lower than the cytotoxic concentration. In both cell lines there was a 2 log inhibition of infectivity. The compound inhibited viral multiplication in a dose-dependent manner and had no virucidal effect. Enterocin CRL35 also inhibited the virion-associated host shutoff in infected Vero cells showing that intracellular viral multiplication was affected.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493605     DOI: 10.1016/s0924-8579(99)00078-3

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  17 in total

1.  Enhancement of the enterocin CRL35 activity by a synthetic peptide derived from the NH2-terminal sequence.

Authors:  Lucila Saavedra; Carlos Minahk; Aída P de Ruiz Holgado; Fernando Sesma
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Physiological and Structural Differences Between Enterococcus faecalis JH2-2 and Mutant Strains Resistant to (P)-Divercin RV41.

Authors:  S Calvez; A Kohler; H Prévost; T Møretrø; D Drider
Journal:  Probiotics Antimicrob Proteins       Date:  2010-12       Impact factor: 4.609

Review 3.  The continuing story of class IIa bacteriocins.

Authors:  Djamel Drider; Gunnar Fimland; Yann Héchard; Lynn M McMullen; Hervé Prévost
Journal:  Microbiol Mol Biol Rev       Date:  2006-06       Impact factor: 11.056

4.  Improvement of enterocin P purification process.

Authors:  S Cuozzo; S Calvez; H Prévost; D Drider
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

Review 5.  Antiviral potential of lactic acid bacteria and their bacteriocins.

Authors:  I Al Kassaa; D Hober; M Hamze; N E Chihib; D Drider
Journal:  Probiotics Antimicrob Proteins       Date:  2014-12       Impact factor: 4.609

6.  Bacteriocins: Not Only Antibacterial Agents.

Authors:  Djamel Drider; Farida Bendali; Karim Naghmouchi; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2016-12       Impact factor: 4.609

7.  Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin.

Authors:  V M Quintana; N I Torres; M B Wachsman; P J Sinko; V Castilla; M Chikindas
Journal:  J Appl Microbiol       Date:  2014-08-23       Impact factor: 3.772

8.  In vivo activities of recombinant divercin V41 and its structural variants against Listeria monocytogenes.

Authors:  Jitka Rihakova; Jean-Michel Cappelier; Isabelle Hue; Katerina Demnerova; Michel Fédérighi; Hervé Prévost; Djamel Drider
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

9.  Safety, formulation, and in vitro antiviral activity of the antimicrobial peptide subtilosin against herpes simplex virus type 1.

Authors:  Nicolás I Torres; Katia Sutyak Noll; Shiqi Xu; Ji Li; Qingrong Huang; Patrick J Sinko; Mónica B Wachsman; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2013-03-01       Impact factor: 4.609

10.  Otitis Media: A Review, with a Focus on Alternative Treatments.

Authors:  L M T Dicks; H Knoetze; C A van Reenen
Journal:  Probiotics Antimicrob Proteins       Date:  2009-03-04       Impact factor: 5.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.